This spectrum consists of isolated hepatic macrovesicular steatosis at one end and nonalcoholic steatohepatitis (NASH) at the other. Hepatic steatosis is present in ~50% of the subjects with HCV.
The presence of macrovesicular steatosis, hepatocyte ballooning, and lobular inflammation on liver biopsy are features of MASH that distinguish MASH from MASLD, which is not associated with these ...
Background: Biopsy is the usual gold standard for liver steatosis assessment. The aim of this study was to identify a panel of biomarkers (SteatoTest), with sufficient predictive values ...
Design We quantified fatty liver parameters and the levels of miR-132 and its targets in novel transgenic mice overexpressing miR-132, in liver tissues from patients with NAFLD, and in diverse mouse ...
We found that insulin treatment aggravated hepatic steatosis and oxidative stress in Zucker diabetic fatty (ZDF) rats. In addition to glycaemic control, we demonstrated the stimulatory role of ...
It can progress from simple hepatic steatosis (MAFL) to more severe conditions like Metabolic-Associated Steatohepatitis (MASH), fibrosis, cirrhosis, and Hepatocellular Carcinoma (HCC). There is a ...
Finally, we determined the influence of hepatocyte-specific PPARα deficiency in different models of steatosis and during ageing. Peroxisome proliferator-activated receptor α (PPARα) is a nuclear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback